AJANTPHARM vs INDOCO: Stock Comparison

Ajanta Pharma Limited vs Indoco Remedies Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Ajanta Pharma Limited is the larger company by market capitalisation. Ajanta Pharma Limited shows a higher ROE, a higher dividend yield and lower leverage, while Indoco Remedies Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Ajanta Pharma Limited and Indoco Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AJANTPHARM is more favourable on 8 of 13 scored metrics and INDOCO on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AJANTPHARM is the larger company
₹43,353 Cr vs ₹2,160 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 42.25x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 9.86x
EPS
AJANTPHARM has higher earnings per share
₹87.24 vs ₹-10.71
Dividend Yield
AJANTPHARM has a higher dividend yield
1.61% vs 0.08%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 21.5%
EPS Growth (TTM YoY)
AJANTPHARM has faster EPS growth
18.6% vs 0%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs 21.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAJANTPHARMINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAJANTPHARMINDOCO
Live Price₹3,475₹233.99
Day Change-2.81%-4.82%
Volume83,48971,688
52-Week High₹3,598.8₹336
52-Week Low₹2,329.9₹162.19
Distance from 52W High-3.44%-30.36%

Valuation

MetricAJANTPHARMINDOCO
Market Cap₹43,353 Cr₹2,160 Cr
P/E Ratio42.25x-23.83x
P/B Ratio9.86x2.41x
EPS₹87.24₹-10.71
Book Value₹362.41₹111.55
Dividend Yield1.61%0.08%

Growth

MetricAJANTPHARMINDOCO
Revenue Growth (TTM YoY)21.5%21.9%
EPS Growth (TTM YoY)18.6%0%
Qtr Sales Growth21.5%21.9%
Qtr Profit Growth18.4%39%

Profitability & Leverage

MetricAJANTPHARMINDOCO
ROE27.1%-9.42%
ROCE34.5%0.93%
Net Margin19.38%-5.31%
Operating Margin27.5%7.68%
Debt to Equity0.06x1.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAJANTPHARMINDOCO
Promoter Holding63.48% 2.77 pp58.86%
FII Holding7.68% 0.58 pp1.27% 0.33 pp
DII Holding21.8% 3.43 pp17.68% 0.47 pp
Public Holding7.03% 0.09 pp22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Ajanta Pharma Limited and Indoco Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.